Intellia Therapeutics Hits Day High with 7.44% Surge in Stock Price

Intellia Therapeutics, Inc. has experienced a significant uptick in its stock performance, gaining 7.44% on February 24, 2026. The stock reached an intraday high of USD 13.84, reflecting a notable day of trading activity. Over the past week, Intellia has shown a robust performance with a 14.41% increase, significantly outpacing the S&P 500's 1.07% gain during the same period. Despite the recent surge, the company's longer-term performance metrics reveal a more complex picture. Over the past year, Intellia's stock has returned 11.59%, slightly below the S&P 500's 12.95%. Year-to-date, however, the company has achieved an impressive 51.06% increase, contrasting sharply with the S&P 500's modest 0.94% gain. Intellia operates within the Pharmaceuticals & Biotechnology industry, with a market capitalization of USD 1,464 million. The company currently holds a high institutional ownership rate of 100%, indicating strong backing from institutional investors. However, it is important to note that the company has faced challenges in profitability, with a return on equity of -58.64% and a significant decline in operating profit over the past five years.